TABLE 4.
Factors associated to be nonresponder
| Univariate analyses | Multivariate analyses | |||||
|---|---|---|---|---|---|---|
| Covariate | HR | 95% CI | P | HR | 95% CI | P |
| Delta Scr at 1 wk (per 0.1) | 1.33 | 0.66-2.70 | 0.41 | |||
| Delta Scr at 2 wk (per 0.1) | 1.48 | 0.85-2.56 | 0.16 | |||
| Delta Scr at 4 wk (per 0.1) | 1.46 | 1.01-2.12 | 0.04 | 1.39 | 0.97-1.98 | 0.07 |
| Delta Scr at 8 wk (per 0.1) | 1.57 | 0.86-2.90 | 0.14 | |||
| Delta Scr at 10 wk (per 0.1) | 1.58 | 0.81-3.06 | 0.17 | |||
| Delta Scr at follow-up biopsy (per 0.1) | 1.38 | 0.87-2.19 | 0.16 | |||
| Indication for biopsy as for cause | 0.84 | 0.57-1.24 | 0.38 | |||
| Interval from transplant to index biopsy (per mo) | 1.0 | 0.99-1.01 | 0.99 | |||
| Age at transplant (per y) | 0.99 | 0.98-1.01 | 0.48 | |||
| HLA mismatch (per each) | 1.01 | 0.89-1.14 | 0.84 | |||
| Male | 1.28 | 0.86-1.90 | 0.21 | |||
| None white recipient | 0.99 | 0.67-1.48 | 0.99 | |||
| Cause of ESKD DM vs other | 0.79 | 0.46-1.35 | 0.38 | |||
| Living donor | 0.99 | 0.66-1.48 | 0.97 | |||
| Previous transplant | 1.03 | 0.68-1.54 | 0.88 | |||
| Depleting induction | 0.93 | 0.65-1.34 | 0.71 | |||
| MVI scores at index biopsy (per each) | 1.41 | 1.18-1.68 | <0.001 | 1.29 | 1.02-1.64 | 0.03 |
| C4d scores at index biopsy (per each) | 1.16 | 1.01-.35 | 0.04 | 1.23 | 1.02-1.48 | 0.03 |
| Cg scores at index biopsy (per each) | 1.25 | 1.05-1.48 | 0.01 | 1.07 | 0.81-1.40 | 0.62 |
| Sum chronicity scores (per each) | 1.12 | 1.04-1.21 | 0.002 | 1.04 | 0.91-1.19 | 0.57 |
| DSA class II present at index biopsy | 1.54 | 1.04-2.27 | 0.03 | 1.31 | 0.83-2.07 | 0.23 |
| Rituximab for treatment | 1.27 | 0.88-1.85 | 0.19 | |||
Bold values indicate statistically significant value with P <0.05.
cg, transplant glomerulopathy; CI, confidence interval; DM, diabetes; DSA, donor-specific antibody; ESKD, end-stage kidney disease; HR, hazard ratio; MVI, microvascular inflammation; Scr, serum creatinine.